Microglia have diverse actions, ranging from synapse pruning in development to cytotoxic effects in disease. Brain energy metabolism and substrate availability vary under normal and disease states, but how these variations influence microglial function is relatively unknown. Microglia, like most other cell types, express the full complement of gene products required for both glycolytic and oxidative metabolism. Evidence suggests that microglia increase aerobic glycolysis and decrease respiration when activated by various stimuli. Mitochondrial function, glucose availability, and glycolytic rate influence pro-inflammatory gene expression at both transcriptional and posttranslational levels. These effects are mediated through CtBP, an NADH-sensitive transcriptional co-repressor; through effects on NLRP3 inflammasome assembly and caspase-1 activation; through formation of advanced glycation end-products; and by less well-defined mechanisms. In addition to these transcriptional effects, microglial glucose metabolism is also required for superoxide production by NADPH oxidase, as glucose is the obligate substrate for regenerating NADPH in the hexose monophosphate shunt. Microglia also metabolize acetoacetate and b-hydroxybutyrate, which are generated during fasting or ketogenic diet, and respond to these ketones as metabolic signals. b-Hydroxybutyrate inhibits histone de-acetylases and activates microglial GRP109A receptors. These actions suppress microglia activation after brain injury and promote neuroprotective microglia phenotypes. As our understanding of microglial activation matures, additional links between energy metabolism and microglial function are likely to be identified.
. Here we review current understanding of microglial energy metabolism and how energy metabolism influences microglial function.
| E N ER GY S U BS TR A TES IN N OR M AL A ND I N J U RE D CN S
The central nervous system is unique in requiring a continuous supply of glucose for normal function. All other tissues, including the heart, can readily metabolize fatty acids, amino acids, and ketones in place of glucose substrate, but the blood brain barrier prevents rapid influx of these alternative substrates under most conditions (Siesj€ o, 1978) . Glucose is metabolized almost completely to CO 2 in normal brain. There can be transient increase in glucose metabolism to lactate in response to local brain activity, but the lactate thus produced is subsequently metabolized oxidatively, or else escapes into the venous system (Dienel, 2012) . Blood glucose concentrations are normally 4-6 mMol/ L, essentially all of which can be extracted by brain. Normal, fully oxygenated blood carries 9 mmol/L O 2 , of which only a portion can be extracted (Siesj€ o, 1978) . There is a glucose concentration gradient between blood and brain, with normal cerebrospinal fluid glucose values in the range of 2-3 mMol/L, and normal extracellular glucose values being about 1.5 mMol/L. There is similarly a gradient to oxygen, with brain parenchyma containing about 2 mMol/L O 2 . Since 6 moles of O 2 are required to oxidize each mole of glucose, this leaves a large excess of glucose available for anaerobic metabolism to lactate when blood delivery of oxygen falls short of demand. This can occur during hypoxia, but also occurs in conditions such as stroke, brain trauma, and increased intracranial pressure. Under these conditions, the rate of glucose utilization in the ischemic brain can be increased by elevated blood glucose concentration (hyperglycemia). The resulting anaerobic glucose metabolism can generate substantial amounts of ATP, but also produces lactic acid (as occurs normally in exercising muscle).
With reductions in blood glucose, as occur during fasting or strenuous exercise, the ketones acetoacetate and b-hydroxybutyrate produced by peripheral fat metabolism can be used by brain to supplement glucose as an energy source. Ketones enter brain through monocarboxylic transporters (MCTs) at the blood-brain barrier at a rate influenced by both blood ketone concentration and MCT expression level (Halestrap & Price, 1999) . Fasting increases MCT expression at the blood-brain barrier, and ketones can provide the majority of brain energy substrate under starvation conditions. MCTs also transport lactate and pyruvate. Blood-derived lactate provides supports 10% of brain metabolism under basal plasma lactate conditions of 1.0 mmol/L, and higher percentages at supra-physiological plasma lactate concentrations (Boumezbeur et al., 2010) .
| M I CR OGL I A U TI LI ZE BOT H OX ID A TI V E A N D GLY COL YTI C EN ER GY M ET AB OLI SM
Direct data on the relative contributions of glycolytic and oxidative ATP production in microglia in situ are not available. As an indirect assessment, we compared the mRNA levels of genes related to energy metabolism in neurons, microglia and astrocytes, using a database of cell-type specific gene expression generated from acutely dissociated mouse brain (Zhang et al., 2014) , (Figure 1 , Tables 1 and 2 ). This analysis shows that microglia express the full complement of genes required for both glycolytic and oxidative energy metabolism. Perhaps surprisingly, the quantitative expression of genes involved in oxidative metabolism is, in aggregate, comparable or higher in microglia than in neurons and astrocytes (Figure 1 ).
These gene expression data do not necessarily indicate the relative rates and routes of energy metabolism in these cell types, but they do confirm the capacity of microglia in situ to generate ATP by both glycolytic and oxidative pathways.
Microglia express several glucose transporters, with GLUT3 (SLC2A3) being the major isoform (Kalsbeek, Mulder, & Yi, 2016) .
GLUT3 is a passive, facilitated glucose transporter, and it is also the dominate isoform expressed by neurons (Vannucci, Maher, & Simpson, 1997) . Unlike other cell types in brain, microglia also express GLUT5 (SLC2A5; Payne, Maher, Simpson, Mattice, & Davies, 1997;  see also Table 2 ). GLUT5 is classified as a fructose transporter because it has a high affinity for fructose and relatively low affinity for glucose. As fructose is present only at low concentrations in brain, the physiological role of this transporter on microglia remains obscure (Douard & Ferraris, 2008) . Microglia are also able to take up ketones and lactate, through the monocarboxylic transporters MCT1 and MCT2 (Moreira et al., 2009) . The extent to which these nonglucose substrates fuel microglial function is unknown, but ketones have been shown to influence microglial function (as further described below).
Quiescent microglia are thought to rely primarily upon oxidative phosphorylation for ATP production (Bernhart et al., 2010; Chenais, Morjani, & Drapier, 2002; Moss & Bates 2001; Won et al., 2012) . Activated microglia in culture increase lactate production, decrease mitochondrial oxygen consumption, and decrease mitochondrial ATP production, indicative of an increased reliance on glycolysis (Gimeno-Bayon, Lopez-Lopez, Rodriguez, & Mahy, 2014; Voloboueva, Emery, Sun, & Giffard, 2013) . A switch from oxidative phosphorylation to aerobic glycolysis has likewise been shown to occur in macrophages as they transition between resting and activated states (Galvan-Pena & O'Neill, 2014) . However, the concept that activated microglia shift to glycolytic energy production does not cleanly fit with observations of microglial mitochondrial density. In cultured rat microglia, stimulation by lipopolysaccharide (LPS) and interferon-g increases the abundance of microglial mitochondria (Banati et al., 2004; Ferger et al., 2010) . Microglial activation is also associated with de novo synthesis of mitochondrial translocator protein (Venneti, Lopresti, & Wiley, 2006) , suggesting that the increased mitochondrial number is attributable to mitochondrial biogenesis rather than mitochondrial fission.
While it seems reasonable to assume that impaired capacity for energy production would influence microglial function, there is only limited information available in this area. Reduced substrate
availability has been shown to induce stress granule formation in cultured microglia. Cytosolic stress granules are irregular complexes of RNA and RNA binding proteins (Hanson & Mair, 2014; Krisenko et al., 2015) , and in microglia they stimulate the production of reactive oxygen and nitrogen species through activation of spleen tyrosine kinase and its downstream substrates such as NFjB . The mitochondrial toxins carbon monoxide, rotenone, and 3-nitroproprionate each influence LPSinduced cytokine production by cultured microglia (Ferger et al., 2010; Wilson et al., 2017) ; however, glycolytic capacity can often fully compensate for impaired mitochondrial ATP production in cultured cells, and consequently the effects of these toxins may be indirect. More direct evidence that bioenergetic capacity can influence microglial function comes from studies of mice deficient in triggering receptor expressed on myeloid cells-2 (TREM2). TREM2 is a microglial surface receptor that is required for normal microglial responses to dead and damaged cells. TREM2 deficient microglia in mouse brain exhibit, in addition to functional impairment, a reduced mitochondrial mass, increased AMPK phosphorylation (indicating low energy status), and increased autophagy (Ulland et al., 2017) . Manipulations that reconstitute TREM2 intracellular signaling or support ATP synthesis reverse all of these abnormalities, suggesting that the functional impairment stems from bioenergetic compromise.
| GL U COS E A ND M I CR OGL IA L R OS P ROD U CTI ON
Independent of its role in energy metabolism, glucose is also required for the quenching of ROS and for repairing oxidative damage to cells
Comparative expression profile analysis of genes related to oxidative and glycolytic metabolism in astrocytes, neurons and microglia. The FPKM (Fragments Per Kilobase of transcript sequence per Million mapped fragments) data, previously reported in (Zhang et al. 2014 ) and available at http://web.stanford.edu/group/barres_lab/brain_rnaseq.html, was exported and analyzed using a cut-off value of 5 FPKM in at least one sample. Stacked bar columns show the expression of oxidative (a) and glycolytic (b) metabolism-related genes in astrocytes, neurons and microglia. Colors represent individual genes, listed in Tables 1 and 2 . (c) Canonical pathways related to the oxidative and glycolytic metabolism in each cell type as assigned by Ingenuity Pathway Analysis software (IPA) (http://www.ingenuity.com/index. html). Horizontal axis shows the-log(P value) for the pathways in each cell type, based on the probability that genes in each cell type were included in the predefined IPA canonical pathways by true association as opposed to random chance. Dotted line shows P 5 .05 through glutathione and thioredoxin-coupled pathways. This is because glucose is the exclusive substrate for the hexose monophosphate shunt (Figure 2 ). NADPH produced by the hexose monophosphate shunt is required by glutathione reductase to convert oxidized glutathione (GSSG) back to reduced glutathione (GSH), the major thiol anti-oxidant in brain, and likewise required for reducing thioredoxin to its active form (Mustacich & Powis, 2000) . Glucose is also used by cells to generate ROS. One way this occurs is by fueling the mitochondrial electron transport chain.
Glucose is normally the origin of the vast majority of reducing Nicholls & Ferguson, 2013; Starkov et al., 2004) . The rate at which this process generates superoxide in healthy cells is considered very low, far below the early estimate of 2% of respiratory oxygen flux obtained using isolated (cell-free) mitochondria (Boveris, 1977) . However, this rate becomes appreciable during ischemia-reperfusion (Niatsetskaya et al., 2012) , in damaged or defective mitochondria (Hayashi & Cortopassi, 2015) , and in the presence of mitochondrial toxins (Adam-Vizi, 2005; Nicholls & Ferguson, 2013) .
A second way that glucose fuels ROS production is through generating NADPH (via the hexose monophosphate shunt) for enzymatic production of nitric oxide and superoxide (Figure 2 ). Microglial inducible nitric oxide synthase (iNOS) uses NADPH and L-arginine as substrates to generate nitric oxide (Possel, Noack, Putzke, Wolf, & Sies, 2000) . Nitric oxide is non-polar, lipid permeable, and has a relatively long half-life and diffusion distance in brain (Pacher, Beckman, & Liaudet, 2007) . Superoxide, by contrast, is polar, largely lipid impermeable, and has a relatively short half-life and diffusion distance (Pacher et al., 2007) . Neither of these ROS are intrinsically highly cytotoxic, but both can be further metabolized to produce highly reactive and cytotoxic species such as hypochlorous acid, peroxynitrite, and hydroxyl radical. consumption by mitochondria, a process termed as "respiratory burst".
This rapid superoxide production requires the continuous metabolism of glucose by the hexose monophosphate shunt for supply of NADPH substrate (Cohen & Chovaniec, 1978; Decoursey & Ligeti, 2005) .
Whether microglia are likewise capable of very rapid superoxide production has not been established, but it is nevertheless likely that the ability of microglia to generate superoxide is dependent upon glucose availability. To directly test this idea, we treated primary mouse microglial cultures with bacterial LPS to activate NOX2, and evaluated superoxide production in the presence and absence of glucose in the medium (Figure 3 ). The medium was supplemented with glutamine as an energy source to prevent ATP depletion. LPS induced a robust superoxide production in medium containing glucose (4 mM), as detected by dihydroethidium oxidation. By contrast, superoxide production was negligible in medium that did not contain glucose (Figure 3 ).
The link between glucose and ROS production may also be relevant to the deleterious effects of elevated blood glucose FIG URE 2 Glucose fuels both ROS scavenging and ROS production. Glucose metabolized through the hexose monophosphate shunt provides reducing equivalents for regenerating NADPH from NADP 1 . NADPH in turn is used by glutathione reductase (GR) to regenerate glutathione (GSH) from glutathione disulfide (GSSG). GSH is used for enzymatic and non-enzymatic scavenging of ROS, and for repair of proteins that have been oxidized by ROS. However, NADPH derived from the hexose monophosphate shunt is also a requisite cofactor for the production of nitric oxide (NO . ) by nitric oxide synthase and superoxide (O :
2 ) by NADPH oxidase (NOX). Glucose metabolized through glycolysis provides reducing equivalents for regenerating NADH from NAD 1 . These reducing equivalents (electrons) normally transit the mitochondrial electron transport chain in the process of generating CO 2 and ATP, but under some conditions a substantial fraction of these electrons are instead captured by oxygen to form superoxide. (Adapted from (Robbins & Swanson, 2014) GHOSH ET AL. | 1205 (hyperglycemia) in brain ischemia-reperfusion (Bruno et al., 1999; Martini & Kent, 2007; Myers & Yamaguchi, 1977; Parsons et al., 2002; Ribo et al., 2005) . A widely cited mechanism by which hyperglycemia can exacerbate brain injury is by increasing lactic acid production and thereby reducing pH in hypoxic tissue (Plum, 1983) ; however, elevated glucose exacerbates ischemic injury even when acidosis is minimal (D'Alecy, Lundy, Barton, & Zelenock, 1986; Park, Chang, & Lee, 2001; Venables, Miller, Gibson, Hardy, & Strong, 1985) and in hypoxic brain slices where pH is tightly controlled (Newell, Barth, Papermaster, & Malouf, 1995; Rytter, Cronberg, Asztely, Nemali, & Wieloch, 2003) . Hyperglycemia increases superoxide production from neurons during ischemia-reperfusion, and NOX2 inhibition prevents both the increased superoxide production and increased neuronal death that would otherwise occur Won, Tang, Suh, Yenari, & Swanson, 2011) . It remains to be established if the superoxide production by microglia in the later, inflammatory stage of ischemic injury is likewise increased by high blood glucose concentrations.
| EN E RG Y M E TA BOLI SM A F F EC TS P RO-I NF L AM M A TOR Y G EN E EXP R ESSI ON B Y M I CROG LI A
Inflammatory responses are influenced at the gene transcription level by factors that affect cellular bioenergetic state, such as caloric restriction, ketogenic diet, and the glycolytic inhibitor 2-deoxyglucose (2DG;
FIG URE 3 Superoxide production by microglia requires glucose. (a) LPS induced a robust superoxide production in the microglia in control medium, but not in glucose-free medium. The fluorescent red signal is produced by oxidized dihydroethidium. Lack of signal in cultures co-treated with NOX inhibitor apocynin (Apo, 10 mM) confirms superoxide as the oxidant species. (b) Quantified data. n 5 3, **P < .01; means 6 SEM. (c) Measures of cellular ATP in cells treated as in A showed no significant decrement in the glucose-free conditions. The mitochondrial inhibitor azide (10 lM) was used as a positive control in presence of glucose. n 5 3, **P < .01 versus control; means 6 SEM. Primary microglia were prepared as described (Saura, Tusell, & Serratosa, 2003) . Experiments were done using DMEM containing no phenol red, 4 mM glutamine, and either 4 or 0 mM glucose. LPS was used at 500 ng/ml. Cells were incubated with dihydroethidium (DHE; 10 mM) for 30 min, then fixed with 4% formaldehyde. Microglia were identified using antibody to Iba1 (ab10709, Abcam) and green fluorescent secondary antibody. Cell nuclei are labelled with DAPI (blue). Superoxide production was quantified as described (Brennan et al., 2009 ). For ATP measurements, cells were lysed after 30 min intervals using detergent supplied by the Abcam luminescence ATP detection assay kit (ab113849). Luminescence was measured in parallel with ATP standards treated identically. Cultures were visually inspected to confirm no significant well-to-well variation in cell number. Data were obtained from 3 independent experiments, each with 2-3 internal replicates. Statistical comparisons were made by ANOVA with Bonferroni's test. All studies were approved by the San Francisco Veterans Affairs Medical Center animal studies committee Goth, 1959; Longo & Mattson, 2014) . Calorie restriction, ketogenic diet, and 2DG each produce a ketogenic state in which glucose utilization is suppressed, and they also reduce inflammation, tissue loss, and functional impairment after brain injury (Appelberg, Hovda, & Prins, 2009; Gasior, Rogawski, & Hartman, 2006; Loncarevic-Vasiljkovic et al., 2012; Tu, Lu, Huang, Ho, & Chou, 2012; Wang et al., 2009; Yu & Mattson, 1999 ). Examples of this are shown in Figure 4 . In these studies, LPS was used as an inflammatory stimulus, and the reduced glycolytic flux resulting from caloric restriction was mimicked by the glycolytic inhibitor 2DG (Garriga-Canut et al., 2006; Yao, Chen, Mao, Cadenas, & Brinton, 2011) . Systemic (intraperitoneal) administration of LPS to rats induced a robust activation of brain microglia, and this was attenuated by co-administration of 2DG (Figure 4a ). In organotypic brain slice cultures (Figure 4b ), 2DG likewise suppressed the effect of LPS on microglial activation and on the expression of iNOS, a hallmark of inflammatory activation in microglia and macrophages (Forstermann & Kleinert, 1995) . Primary microglial cultures similarly showed an attenuated response to LPS in the presence of 2DG (Figure 4c ), thus confirming that the effects of LPS and 2DG on microglia are not dependent upon indirect, systemic effects of these agents.
Recent studies have identified several mechanisms by which glucose levels can influence pro-inflammatory gene transcription. One of these mechanisms involves the formation of advanced glycation end products (AGE), which are modifications of proteins and lipids resulting from non-enzymatic reactions with sugars. AGE formation is generally a slow process, but is accelerated under high glucose levels. Microglia express receptors for advanced glycation end-products, which stimulate pro-inflammatory signaling pathways when activated (Bianchi, Giambanco, & Donato, 2010; Chen et al., 2017) . Glycolytic rate (though not necessarily glucose levels per se) can also influence formation of FIG URE 4 Glucose metabolism affects microglial activation and ROS production at the transcriptional level. (a) Immunostaining for CD11b identifies activated microglia in rat hippocampus. CD11b expression was increased 24 hr after intraperitoneal injection with LPS (10 mg/kg). The increase was attenuated by co-injection with the glycolytic inhibitor 2-deoxyglucose (2DG; 100 mg/kg). Scale bar 5 100 mm. **P < .01, n 5 6. (b) Immunostaining for Iba1 and iNOS identify activated microglia in mouse hippocampal slice cultures after 24 hr incubation with LPS (10 lg/ml) or LPS 1 2DG (1 mM). Scale bar 5 100 mm; n 3, *P < .05. Culture medium for contained 6 mM glutamine and 5 mM glucose. (c) Effects of 1 mM 2DG on LPS-induced iNOS transcript and protein expression in microglial cultures. n 5 5; *P < .05, **P < .01. Data are means 6 SEM. Figure adapted from (Shen et al., 2017) GHOSH ET AL.
| 1207 NLRP1 and NLRP3 inflammasomes. Inflammasomes are responsible for caspase 1 activation, which is required for maturation and secretion of IL-1b and other cytokines (Franchi, Eigenbrod, Munoz-Planillo, & Nunez, 2009) . Increased glycolytic rate facilitates NLRP3 assembly in macrophages, (Moon et al., 2015; Xie et al., 2016) , by a mechanism that remains to be established. In brain, NLRP3 inflammasomes are
found in microglia but not in astrocytes (Gustin et al., 2015) . Intermittent fasting was shown to suppress post-ischemic expression of inflammasomes, and this effect was associated with reduced Il1-b and reduced NF-jB signaling in the post-ischemic brain (Fann et al., 2014 ).
An additional, more direct way that glucose metabolism exerts transcriptional control over microglial activation is through an NADHsensitive co-repressor termed C-terminal binding protein (CtBP). Factors that slow glucose flux through glycolysis, such as reduced glucose availability or glycolytic inhibitors, reduce NADH levels and thereby reduce NADH:NAD 1 ratio. By contrast, factors that slow oxidative metabolism, such as hypoxia and mitochondrial inhibitors, have the opposite effect (Figure 5a ). The resulting relative changes in NADH are several hundred-fold greater than the reciprocal changes in NAD 1 because the cytosolic NADH:NAD 1 ratio is normally in the range of 1:700 (Ying, 2008) . For this reason, changes in cytosolic NADH levels provide a highly sensitive measure of changes in glycolytic flux.
The CtBPs are among a very limited number of NADH-sensitive proteins known to influence gene transcription (Ghosh, George, Roy, Ramachandran, & Kolthur-Seetharam, 2010) . CtBP in its monomeric form suppresses the activity of the acetyltransferase p300/CBP (Kim, Cho, Kim, & Youn, 2005) , which acetylates both histones and the proinflammatory transcription factor, NF-jB (Chen, Mu, & Greene, 2002) .
Increased NADH levels promote the formation of CtBP dimers, and thereby modulate CtBP association with its binding partners (Zhang, Piston, & Goodman, 2002) . In microglia and the macrophage RAW264.7 cell line, glucose flux was shown to regulate the expression of iNOS and other pro-inflammatory genes by a mechanism involving CtBP sensing of cytosolic NADH levels (Shen et al., 2017) . This mechanism may more generally couple glucose metabolism to innate immune reactivity ( Figure 5c ).
| D I R ECT EF F EC TS OF KET ONE S ON M I CR OGL I AL A CTI V A TI ON
Sustained reductions in blood glucose levels lead to a rise in circulating ketones, as peripheral fat is metabolized to acetoacetate, b-hydroxybutyrate, and their breakdown product acetone. A ketogenic state is common in animals in the wild, and occurs in humans during fasting and extended exercise. Fasting and ketogenic diet have well-established anti-inflammatory effects, including suppression of microglial activation (Fann et al., 2014; Gasior et al., 2006; Longo & Mattson, 2014) . These effects are mediated in part by direct signaling by ketones on microglia and macrophages.
b-Hydroxybutyrate activates G-protein-coupled receptors 109A
(GPR109A) and inhibits histone de-acetylases (Huang et al., 2017; Newman & Verdin, 2014; Rahman et al., 2014) . In microglia, the activation of GPR109A by b-hydroxybutyrate attenuates NF-kB signaling and pro-inflammatory cytokine production (Fu et al., 2015) .
Activation of GPR109A also promotes a neuroprotective phenotype in microglia/macrophages, and in a mouse stroke model the beneficial and anti-inflammatory effects of ketogenic diet are lost in mice lacking the GPR109A receptor. Microglia and macrophages also express other metabolite receptors in addition to GPR109A, but the effects on these on microglia function remain to be established.
| CON CL U S I ONS
As "sentinels" of the nervous system, it is fitting that microglia respond to changes in brain metabolism. It has been recognized for decades that bioenergetic factors influence innate immune responses (Goth, 1959) , but only recently have some the mechanisms that underlie these effects been identified. As our understanding of microglial activation becomes more nuanced and complete, we can likely expect to find additional links between bioenergetic factors and specific aspects of activation, such as specific gene expression patterns or morphological changes. However, microglia are normally in a state that is "quiescent" 
